ImmunoPET as Stoichiometric Sensor for Glypican-3 in Models of Hepatocellular Carcinoma
| Autor: | Nicholas T. Gutsche, Meghan Bell, Olivia J. Kelada, Blake M. Warner, Freddy E. Escorcia, Jessica Hong, Kwamena E. Baidoo, Mitchell Ho, Peter L. Choyke, Rose M. Berman, Lawrence P. Szajek |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
Biodistribution Radiation medicine.diagnostic_test Chemistry business.industry Cancer Immunofluorescence medicine.disease Glypican 3 030218 nuclear medicine & medical imaging Flow cytometry 03 medical and health sciences 0302 clinical medicine Oncology In vivo 030220 oncology & carcinogenesis Monoclonal Cancer research Medicine Radiology Nuclear Medicine and imaging business Liver cancer |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 108:S180-S181 |
| ISSN: | 0360-3016 |
| Popis: | BackgroundHepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. While conventional imaging approaches like ultrasound, CT, and MRI play critical roles in the diagnosis and surveillance of HCC, improved methods for detection and assessment of treatment response are needed. One promising approach is the use of radiolabeled antibodies for positron emission tomography (immunoPET) imaging. Glypican-3 (GPC3) is a proteoglycan that is highly expressed in the majority of HCC tumors. GPC3-specific antibodies are used to diagnose HCC histopathologically, and have been proposed as a treatment of HCC. Here, we design, synthesize and demonstrate that our humanized immunoPET agent, [89Zr]Zr-DFO-TAB-H14, can stoichiometrically bind to models of human liver cancer with varied GPC3 expression. Methods: The GPC3-specific monoclonal humanized IgG1, TAB-H14, was used as a scaffold for engineering our immunoPET agent. Fluorescent and deferroxamine (DFO) chelate conjugates of TAB-H14 were characterized using mass spectrometry. Binding affinity of TAB-H14 and conjugates for GPC3 was determined in cell-free biolayer interferometry, and cell-based radioimmunoassays. GPC3-expression was assessed by flow cytometry and immunofluorescence using commercially available anti-GPC3 antibodies and TAB-H14 in GPC3−(A431) and GPC3+cell lines including an engineered line (A431-GPC3+, G1) and liver cancer lines (HepG2, Hep3B, and Huh7). DFO-TAB-H14, was radiolabeled with Zr-89. Mice were subcutaneously engrafted with the aforementioned cell lines and in vivo target engagement of the immunoPET agent [89Zr]Zr-DFO-TAB-H14 was determined using PET/CT, quantitative biodistribution, and autoradiography. Results: TAB-H14 demonstrated subnanomolar to nanomolar affinity for human GPC3. Fluorescently tagged TAB-H14 was able to bind to GPC3 on cell membranes of GPC3-expressing lines by flow cytometry. These results were confirmed by immunofluorescence staining of A431, G1 HepG2, Hep3B, and Huh7 tumor sections. ImmunoPET imaging with [89Zr]Zr-DFO-TAB-H14 showed stoichiometric tumor uptake corresponding to the cell surface expression levels. Autoradiography and immunostaining confirmed in vivo findings. Conclusion: We systematically demonstrate that the humanized immnoPET agent [89Zr]Zr-DFO-TAB-H14 specifically and stoichiometrically binds to GPC3 in several models of human liver cancer, serving as a promising in vivo GPC3 sensor. This agent may provide utility in HCC diagnosis and surveillance, and the selection of candidates for GPC3-directed therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|